A Review of Recent Advance Therapy of The MDR TB and DR TB

TB still causes a significant amount of illness and mortality across the world, even after the low-cost and successful four-drug treatment regimen (isoniazid, rifampicin, pyrazinamide, and ethambutol) was introduced 40 years ago. For all types of tuberculosis, new and innovative medications and treatment plans are being developed for the first time since the 1960s. Both novel chemical entities and repurposed medications are anticipated to be used in such regimens, some of which are now advancing through clinical studies. Current ideas and recent developments in TB drug discovery and development are discussed in this article. These include an update on ongoing TB treatment studies, updated clinical trial designs, TB biomarkers, and adjunct host-directed medicines.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-04-22
DOI
https://doi.org/10.5281/zenodo.15259902
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Review of Recent Advance Therapy of The MDR TB and DR TB

Zenodo (CERN European Organization for Nuclear Research)
Tuberculosis Research and Epidemiology
article

A Review of Recent Advance Therapy of The MDR TB and DR TB

article en

Abstract

TB still causes a significant amount of illness and mortality across the world, even after the low-cost and successful four-drug treatment regimen (isoniazid, rifampicin, pyrazinamide, and ethambutol) was introduced 40 years ago. For all types of tuberculosis, new and innovative medications and treatment plans are being developed for the first time since the 1960s. Both novel chemical entities and repurposed medications are anticipated to be used in such regimens, some of which are now advancing through clinical studies. Current ideas and recent developments in TB drug discovery and development are discussed in this article. These include an update on ongoing TB treatment studies, updated clinical trial designs, TB biomarkers, and adjunct host-directed medicines.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 46%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.